GlassScriptPhysician profile
Charles N Buser
NPI 1366736373
$606.29
in general payments reported to CMS, 2019-2025
18 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $30.19 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $283.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $81.31 | 2019 | |
| Advanced Medical Administration | $62.40 | 2025 | Amniograft |
| Amgen INC. | $59.62 | 2019-2020 | |
| Gilead Sciences, INC. | $55.95 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $45.03 | 2019-2025 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.16 | 2019 | |
| Lilly USA, LLC | $33.48 | 2019-2025 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $33.42 | 2019 | |
| Corcept Therapeutics | $31.74 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $25.54 | 2019 | |
| Exact Sciences Corporation | $24.00 | 2025 | The Cologuard Plus Collection Kit |
| Viatris Specialty LLC | $18.90 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $18.00 | 2025 | Trelegy Ellipta |
| Ascendis Pharma Endocrinology INC | $17.60 | 2025 | Yorvipath |
| Astellas Pharma US INC | $16.88 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.57 | 2025 | Ozempic |
| Daiichi Sankyo INC. | $13.94 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.75 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Buser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.